HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.